Active organotypic models for nanoparticle toxicological screening
Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers.
However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animal
testing) and functional (high attrition rate in clinical testing) point of view. ActiTOX reacts to this problem by the development
of a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME
(absorption, distribution, metabolism, excretion) toxicity studies. In order to advance the current state of art the project will
employ biomimetic scaffolds, drug delivery systems, human induced pluripotent stem cells (iPSCs), 3D-microfluidics and
modular bioreactor technology. ActiTOX aims to increase the relevance of in vitro studies and provide a scalable approach
for their use in drug development and toxicological screening.
In order to achieve the project goals, a training network enabling efficient short-term secondments of ER and ESR between
academia and industry will be established. The cooperation between stakeholders helps closing the gap between them and oint innovation to foster the current state of the art. ActiTOX will mediate it via networking, research, training, workshop,
innovation and dissemination actions in form of short-term secondments. The project fulfils the aim of a RISE project and
delivers significant social impact, increases knowledge based economy and creates long lasting cooperation strengthening
the European research area.